Neutral
●
GlobeNewsWire
●
5 months ago
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics, Inc. may have issued materially misleading business information to the investing public.